Navigation Links
Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis

HERCULES Trial Aims to Treat Renal Artery Obstructions and Lower Blood

Pressure in Patients Not Responding to Medication

ABBOTT PARK, Ill., Sept. 25 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced enrollment of the first patient in HERCULES (Herculink Elite Cobalt Chromium Renal Stent Trial to Demonstrate Efficacy and Safety), a U.S. clinical trial designed to evaluate the safety and effectiveness of the investigational RX Herculink(R) Elite(TM) Renal Stent System to treat patients with renal artery stenosis (RAS), a condition characterized by fatty plaque buildup in the kidney arteries that can lead to high blood pressure. The first implant was performed by Joaquin Martinez de Arraras, M.D., FACC, president of Amarillo Heart Clinical Research Institute, Inc. in Amarillo, Texas.

In renal artery stenosis, a buildup of fatty plaque causes narrowing of the renal arteries that lead to the kidneys, organs that filter waste from the blood. In patients who have uncontrolled high blood pressure (hypertension) without apparent cause, renal artery stenosis is often discovered as the culprit during clinical investigation. Renal artery stenosis affects approximately 5 million people in the United States, and occurs most often in men between the ages of 50 and 70. It can lead to poor kidney function, or even kidney failure and dialysis, which is a risk factor for cardiovascular disease.

"Many patients with high blood pressure and renal artery stenosis do not respond as well to medication alone as they may to medication plus stenting," said Dr. Martinez de Arraras. "The goal of the HERCULES trial is to evaluate whether renal artery stenting may reduce vessel renarrowing, thereby potentially reducing other risk factors for cardiovascular disease, such as high blood pressure."

To qualify for the HERCULES study, patients must have uncontrolled hypertension that is not responding to treatment with at least two blood pressure medications, and must have at least 60 percent stenosis or blockage in a renal artery as measured by visual X-ray angiography.

"We are pleased to begin enrollment in a study to examine the safety and effectiveness of stenting for patients with renal artery disease and uncontrolled high blood pressure," said Chuck Foltz, vice president, Abbott Vascular. "Abbott Vascular has a strong history of innovation and leadership in vascular care, and with the HERCULES trial we can continue to expand our understanding of vascular disease and how to deliver the best treatments for patients."

About the HERCULES Trial

Abbott is conducting the HERCULES trial to seek U.S. Food and Drug Administration approval for use of the RX Herculink Elite Renal Stent System in the treatment of renal artery stenosis.

The HERCULES trial will enroll up to 202 patients at approximately 50 sites across the United States. The primary endpoint of the study is binary restenosis at nine months, a measure of vessel renarrowing. Secondary endpoints in the trial will measure changes in blood pressure and the use of hypertensive medication at nine months. Additional analyses in patient follow-up visits out to 36 months will measure major adverse events in patients such as death, surgical removal of the kidney, or embolic events resulting in kidney damage, as well as target lesion revascularization (TLR), a measure of the need to retreat a diseased vessel that has renarrowed.

About the Investigational RX Herculink Elite Renal Stent System

The RX Herculink Elite Renal Stent System is an .014-inch rapid-exchange (single-operator) renal stent system made of cobalt chromium, a material that is stronger and easier to see under X-ray than stainless steel.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
9. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
10. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
11. Malvern initiates European user group meetings for chemical imaging
Post Your Comments:
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
Breaking Medicine News(10 mins):